Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  DIRECTORS REPORT
Directors Report      
Medplus Health Services Ltd.
March 2019

Description of state of companies affair

STATE OF COMPANY'S AFFAIRS i Segment-wise position of business and its operations During the financial year ended as on 31st March, 2018, the Company recorded a total revenue of 95.20 Millions (Previous financial year 94.23 Millions) and recorded net loss (after considering an amount towards depreciation in accordance with provisions of Schedule II of the Companies Act, 2013) of 25.69Millions (Previous Year loss of 161.63Millions). ii Change in status of the company No change in status of the Company iii Key business developments 1. The Scheme of Amalgamation for merger with Ritemed Pharma Retail Private Limited (Wholly Owned Subsidiary) approved by the members of the Company at the Meeting held on 14th August 2018 became effective on 1st October 2018 upon filing the order dated 14th August 2018 issued by NCLT approving the Scheme of Amalgamation. Consequently, the entire undertaking of Ritemed Pharma Retail Private Limited along with all its assets and liabilities got vested on the Company with effect from the Appointed Date i.e 01.04.2016. Further, as per the clause 7 of the said Scheme, the authorised capital is increased from Rs.1,440,000,000/- to Rs. 1,730,000,000/- and the Paid up Capital of the Company is increased from Rs. 1,415,447,400/- to Rs. 1,728,247,400/- upon combination of Authorised Share Capital of Ritemed Pharma Retail Private Limited with Authorised Share Capital of the Company and the Annual Audited Financial Statements are combination of the Company and Ritemed Pharma Retail Private Limited. Since, your Company holds 100% of the Share Capital of Ritemed Pharma Retail Private Limited, the shareholding in Optival Health Solutions Private Limited has increased on account of merger of Ritemed Pharma Retail Private Limited with Optival Health Solutions Private Limited.

Details regarding energy conservation

The Corporation is taking due care for using electricity in the office and its branches. The Corporation usually takes care for optimum utilization of energy. No capital investment on energy Conservation equipment made during the financial year.

Disclosures in director’s responsibility statement

DIRECTORS' RESPONSIBILITY STATEMENT Pursuant to Section 134(5) of the Companies Act, 2013 the Board of Directors of the Company confirms that- (a) In the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures; (b) The directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period; (c) The directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities; (d) The directors had prepared the annual accounts on a going concern basis; and (e) Company being an listed/unlisted company, the said para is applicable and complied accordingly / not applicable. (f) The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.